Please use this identifier to cite or link to this item:
|Title:||Targeted alpha therapy of glioblastoma multiforme: First clinical experience with 213Bi-substance P|
|Authors:||MORGENSTERN Alfred; KROLICKI Leszek; KUNIKOWSKA Jolanta; KOZIARA H; KROLICKI B; JAKUCINSKI M; APOSTOLIDIS Christos; BRUCHERTSEIFER Frank|
|Citation:||JOURNAL OF NUCLEAR MEDICINE vol. 55 no. Supplement 1 p. 390|
|Publisher:||SOC NUCLEAR MEDICINE INC|
|Type:||Articles in periodicals and books|
|Abstract:||Glioblastoma multiforme (GBM), the most common primary brain tumor in adults, has a very poor prognosis with a median overall survival of 15 months despite of aggressive therapy including surgery, chemotherapy and radiation therapy. Targeted alpha therapy with the short range, high LET alpha emitter 213Bi offers the potential for selective irradiation of tumors, while minimizing damage to adjacent, functional critical areas of the brain. The peptide carrier substance P is targeting NK 1 receptors, which are consistently over-expressed on GBM cells. Here we report the first clinical experience with 213Bi-labeled DOTA-Substance P (213Bi-SP) in patients with recurrent GBM.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.